Cohance Lifesciences enters its Q1 FY27 results following a transition year marked by portfolio shifts and customer-led inventory normalization. Investors will be focused on the company's ability to navigate a flagged weak quarter while managing regulatory remediation at its Nacharam site and executing on its long-term ADC and oligonucleotide growth strategy.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 619.1 Cr |
| Previous quarter PAT | Rs. 33.0 Cr |
| Previous quarter EBITDA margin | 21.0% |
| Net debt (latest quarter) | Rs. 152.7 Cr |
| Market cap | Rs. 16,245.74 Cr |
| CMP | Rs. 425.05 |
The board meeting is scheduled for August 05, 2026, to approve the unaudited Q1 FY27 financial results.
An investor conference call is scheduled for August 05, 2026, at 6:30 PM IST to discuss the Q1 FY27 results.
Management has explicitly cautioned that Q1 FY27 will be a weak quarter for both revenue and EBITDA, with growth expected to return from the second half of the fiscal year. The company is navigating a persistent revenue drag of approximately Rs. 15 Cr per quarter from its Nacharam facility, where a recent April 2026 FDA re-inspection resulted in three Form-483 observations. While the USD/INR depreciation to an average of ~95.5 during the quarter provides a mechanical tailwind for export-heavy revenue, the net margin benefit remains sensitive to the company's unhedged USD-denominated raw material costs. NJ Bio's performance is expected to remain muted as the biotech funding environment for early-stage clients remains at a decade-low, despite a 22% rise in total venture capital dollars in 1H26. The upcoming call will likely focus on the timeline for resolving the Nacharam Warning Letter and the progress of the Rs. 300 Cr capex plan for FY27.
Nacharam facility remediation: Tracking the timeline for US market resumption following the April 2026 re-inspection.
NJ Bio and Niche Technology growth: Assessing the conversion of the bioconjugation pipeline amid biotech funding headwinds.
Financial and leadership transition: Monitoring the impact of management changes and capital allocation.
The Nacharam formulation plant suffered a revenue impact of Rs. 61 Cr in FY26 following an OAI status and subsequent Warning Letter. Production has resumed for non-US markets, but US-market resumption remains gradual.
Management has reaffirmed the long-term target of USD 1 billion in revenue by FY30, although they have noted that the specific timing of this achievement may shift. The company continues to focus on its science engine in ADCs, oligonucleotides, and solid dose capabilities to reach this goal.
Management has indicated that Q1 FY27 would be weak on both revenue and EBITDA due to ongoing portfolio transitions and timing shifts. They have stated that they expect the business to remain stable in Q2, with growth returning from the second half of FY27 onwards.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now